Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a less invasive alternative to BS for managing obesity, with recent studies indicating potential benefits for IBD outcomes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.